Dr. Noc, PhDwhat it claims
Retatrutide, a new peptide compound targeting three appetite and energy-regulating hormones, produces particularly significant weight loss according to the latest stages of its clinical evaluation.
The promise of this new compound is based on solid scientific foundations. Data from Eli Lilly's phase 3 clinical trial (TRIUMPH-1, presented in May 2026)—a large-scale randomized…
